Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Ipamorelin vs Sermorelin

Q: What is the difference between Ipamorelin and Sermorelin?

Ipamorelin is a Growth Hormone Secretagogue compound (Subcutaneous route) - Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration. Sermorelin is a Growth Hormone Secretagogue compound (Subcutaneous route) - Recombinant GHRH 1-29. Published protocols typically schedule administration at bedtime to align with the natural overnight GH pulse.

Q: Which has a longer half-life, Ipamorelin or Sermorelin?

Ipamorelin has the longest published plasma half-life (2 h), compared with Sermorelin (~12 min).

Q: How often is each compound dosed in the research literature?

Ipamorelin: once daily at a published dose range of 0.2–0.3 mg; Sermorelin: once daily at a published dose range of 0.1–0.5 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Ipamorelin and Sermorelin for research use?

Yes - Ipamorelin, Sermorelin are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

IPAMORELIN

Ipamorelin

Growth Hormone Secretagogue

SERMORELIN

Sermorelin

Growth Hormone Secretagogue

Key research differences

Ipamorelin Sermorelin Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Development status Research peptide Research peptide Published half-life 2 h ~12 min Research distinction Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration Recombinant GHRH 1-29. Published protocols typically schedule administration at bedtime to align with the natural overnight GH pulse

Published research parameters

Ipamorelin NNC 26-0161 View Ipamorelin → Sermorelin GHRH 1-29 View Sermorelin → Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Class Growth Hormone Secretagogue Growth Hormone Secretagogue Plasma half-life 2 h ~12 min Time to Cmax ~30 min ~6 min Development status Research peptide Research peptide Study context Educational estimate Peer-reviewed human PK Primary publications Raun K et al., Eur J Endocrinol 139:552 (1998) Walker RF, Clin Interv Aging 1:307 (2006) Summary Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration. Recombinant GHRH 1-29. Published protocols typically schedule administration at bedtime to align with the natural overnight GH pulse.

View published study parameters

Ipamorelin NNC 26-0161 View Ipamorelin → Sermorelin GHRH 1-29 View Sermorelin → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once daily Published dose range 0.2–0.3 mg 0.1–0.5 mg Published study regimen No published study ladder No published study ladder

Source references

Raun K et al.

1998

Raun K et al., Eur J Endocrinol 139:552 (1998)

Walker RF

2006

Walker RF, Clin Interv Aging 1:307 (2006)

Frequently asked questions

What is the difference between Ipamorelin and Sermorelin?

Which has a longer half-life, Ipamorelin or Sermorelin?

How often is each compound dosed in the research literature?

Can you buy Ipamorelin and Sermorelin for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research